Matteo Interlenghi

Dr. Matteo Interlenghi

DeepTrace Technologies, Milan, Lombardy, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Physica Medica
Verified
Journal Article
Closed access
ICIsabella Castiglioni
Isabella Castiglioni
Leonardo RundoLeonardo Rundo
Leonardo Rundo
MCMarina Codari
Marina Codari
GLGiovanni Di Leo
Giovanni Di Leo
CSChristian Salvatore
Christian Salvatore
FSFrancesco Sardanelli
Francesco Sardanelli

7 May 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
MKMargarita Kirienko
Margarita Kirienko
MSMartina Sollini
Martina Sollini
MCMarinella Corbetta
Marinella Corbetta
EVEmanuele Voulaz
Emanuele Voulaz
NGNoemi Gozzi
Noemi Gozzi
ACArturo Chiti
Arturo Chiti
Objective: The objectives of our study were to assess the association of radiomic and genomic data with histology and patient outcome in non-small cell lung cancer (NSCLC). Methods: In this retrospective single-centre observational study, we selected 151 surgically treated patients with adenocarcinoma or squamous cell carcinoma who performed baseline [18F] FDG PET/CT. A subgroup of patients with cancer tissue samples at the Institutional Biobank (n = 74/151) was included in the genomic analysis. Features were extracted from both PET and CT images using an in-house tool. The genomic analysis included detection of genetic variants, fusion transcripts, and gene expression. Generalised linear model (GLM) and machine learning (ML) algorithms were used to predict histology and tumour recurrence. Results: Standardised uptake value (SUV) and kurtosis (among the PET and CT radiomic features, respectively), and the expression of TP63, EPHA10, FBN2, and IL1RAP were associated with the histotype. No correlation was found between radiomic features/genomic data and relapse using GLM. The ML approach identified several radiomic/genomic rules to predict the histotype successfully. The ML approach showed a modest ability of PET radiomic features to predict relapse, while it identified a robust gene expression signature able to predict patient relapse correctly. The best-performing ML radiogenomic rule predicting the outcome resulted in an area under the curve (AUC) of 0.87. Conclusions: Radiogenomic data may provide clinically relevant information in NSCLC patients regarding the histotype, aggressiveness, and progression. Gene expression analysis showed potential new biomarkers and targets valuable for patient management and treatment. The application of ML allows to increase the efficacy of radiogenomic analysis and provides novel insights into cancer biology.

21 July 2020 in Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
VCValentina Chiappa
Valentina Chiappa
GBGiorgio Bogani
Giorgio Bogani
Matteo InterlenghiMatteo Interlenghi
Matteo Interlenghi
CSChristian Salvatore
Christian Salvatore
FBFrancesca Bertolina
Francesca Bertolina
FRFrancesco Raspagliesi
Francesco Raspagliesi

7 December 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
GBGiorgio Bogani
Giorgio Bogani
VCValentina Chiappa
Valentina Chiappa
SLSalvatore Lopez
Salvatore Lopez
CSChristian Salvatore
Christian Salvatore
Matteo InterlenghiMatteo Interlenghi
Matteo Interlenghi
FRFrancesco Raspagliesi
Francesco Raspagliesi
Molecular/genomic profiling is the most accurate method to assess prognosis of endometrial cancer patients. Radiomic profiling allows for the extraction of mineable high-dimensional data from clinical radiological images, thus providing noteworthy information regarding tumor tissues. Interestingly, the adoption of radiomics shows important results for screening, diagnosis and prognosis, across various radiological systems and oncologic specialties. The central hypothesis of the prospective trial is that combining radiomic features with molecular features might allow for the identification of various classes of risks for endometrial cancer, e.g., predicting unfavorable molecular/genomic profiling. The rationale for the proposed research is that once validated, radiomics applied to ultrasonographic images would be an effective, innovative and inexpensive method for tailoring operative and postoperative treatment modalities in endometrial cancer. Patients with newly diagnosed endometrial cancer will have ultrasonographic evaluation and radiomic analysis of the ultrasonographic images. We will correlate radiomic features with molecular/genomic profiling to classify prognosis.

1 March 2022 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
VMVeronica Magni
Veronica Magni
Matteo InterlenghiMatteo Interlenghi
Matteo Interlenghi
ACAndrea Cozzi
Andrea Cozzi
MAMarco Alì
Marco Alì
CSChristian Salvatore
Christian Salvatore
FSFrancesco Sardanelli
Francesco Sardanelli
“Just Accepted” papers have undergone full peer review and have been accepted for publication in Radiology: Artificial Intelligence. This article will undergo copyediting, layout, and proof review ...

11 July 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
ICIsabella Castiglioni
Isabella Castiglioni
FGFrancesca Gallivanone
Francesca Gallivanone
PSPaolo Soda
Paolo Soda
MAMichele Avanzo
Michele Avanzo
JSJoseph Stancanello
Joseph Stancanello
MSMarco Salvatore
Marco Salvatore